KURA vs TXT · rev $20.9M vs P/E 19, rev $7.52B
Kura Oncology Inc (KURA) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Kura Oncology Inc (KURA) is a biotechnology company listed on NASDAQ.
Textron Inc (TXT) is a aerospace & defense company listed on US.
Latest reported KURA revenue for 2026-06-30 was $20.9M. Net income was -$68.3M. Revenue was up 14.3% from 2026-03-31 to 2026-06-30. KURA currently screens at market cap $861.1M.
Latest reported TXT revenue for 2026-07-04 was $7.52B. Net income was $468.0M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
KURA currently screens at market cap $861.1M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the KURA and TXT stock pages for the full models.
Not investment advice.